How does MOTS-c work?
MOTS-c is a naturally occurring peptide made inside your mitochondria, the parts of your cells responsible for producing energy. Almost every other peptide in the body is built from instructions in the nucleus, the cell's main library. MOTS-c is different: its instructions sit inside the mitochondria's own small loop of mitochondrial DNA (Lee et al., 2015).
When the cell is stressed by fasting, cold, exercise, or low fuel, mitochondria release more MOTS-c. The peptide enters the nucleus and helps activate a fuel-sensing enzyme called AMPK, the cellular energy sensor that exercise and the diabetes drug metformin both act through (Kim et al., 2018). The downstream effects are improved glucose uptake into muscle, increased fat use for fuel, and improved insulin signaling.
What Conditions Is It Used For?
Providers may use MOTS-c for the following diseases and conditions:
Insulin resistance and metabolic syndrome
Non-alcoholic fatty liver disease (NAFLD/NASH)
Body composition and metabolic recovery, often alongside or after GLP-1 medications (the appetite-regulating diabetes and obesity drugs like Ozempic and Wegovy)
Aerobic exercise capacity and recovery
Mitochondrial support and age-related fatigue
What to Expect During Treatment
If you’re thinking about the MOTS-c, your provider will typically start by assessing your overall metabolic health. That often means checking blood sugar markers, insulin levels, cholesterol, and liver function to establish a baseline before treatment begins.
Many providers also check homocysteine, folate, and B12, the markers tied to the folate cycle that MOTS-c interacts with. For exercise-focused use, some providers record a VO2 max estimate (the body's maximum oxygen uptake during exercise).
MOTS-c is given as a small subcutaneous injection, usually into the abdominal fat. A common protocol is 0.5 to 2.5 mg, two or three times a week for four to twelve weeks, then a break. Most people don't feel the injection itself. Reported responses build slowly: steadier energy, fewer afternoon crashes, easier aerobic sessions, and modest shifts in body composition after several weeks. Most providers repeat lab work after several weeks to see whether blood sugar, insulin sensitivity, or liver markers are improving.
How MOTS-c Works in Depth
One reason researchers are interested in MOTS-c is that it challenged long-standing assumptions about mitochondria. Scientists once viewed mitochondria primarily as the cell's energy producers, but MOTS-c suggests they may also play a role in signaling and metabolic regulation throughout the body. MOTS-c was the first peptide shown to be coded inside it and released to act on the wider body (Lee et al., 2015).
When cellular energy runs low, MOTS-c production rises. The peptide moves into the cytoplasm (the water-based fluid in a cell) and, under stress, into the nucleus, where it influences which genes the cell turns on (Kim et al., 2018). It activates AMPK, the fuel-sensing enzyme that tells the cell to stop storing energy and start burning it.
Activating AMPK helps muscles use glucose more efficiently and may encourage the body to rely more on stored fat for fuel. MOTS-c also affects the folate cycle, the one-carbon pathway that handles methylation, which is why providers check homocysteine before and after a course.
Skeletal muscle is the main target tissue. MOTS-c rises with exercise, falls with age, and is lower in adults with type 2 diabetes, coronary artery disease, and obesity (D'Souza et al., 2020; Kong et al., 2023; Mohtashami et al., 2022).
How MOTS-c Is Used in Practice
Providers prescribe MOTS-c for a select number of medical conditions, including:
Insulin resistance and metabolic syndrome
This is the most common reason a functional or longevity provider reaches for MOTS-c. The candidate has elevated HOMA-IR, a creeping HbA1c, or visceral fat that hasn't moved with diet and exercise alone. Typical protocols run 0.5 to 2.5 mg two or three times a week for eight to twelve weeks, paired with strength and aerobic training, with labs re-checked mid-course and at the end. Some providers view it as a possible adjunct for people who have already made meaningful changes to their diet and exercise habits but are still struggling with metabolic health.
Non-Alcoholic Fatty Liver Disease
NAFLD and its more inflamed form, NASH, are the indication with the strongest human signal. The CB-4211 trial produced meaningful reductions in liver enzymes and fasting glucose within 4 weeks (CohBar Inc., 2021). In practice, MOTS-c for fatty liver is paired with reduced ultra-processed food intake, weight loss, and sometimes a GLP-1 medication. Liver enzymes and a FibroScan at three months will read whether the combination is working.
Body Composition and Recovery Alongside GLP-1s
A growing application is muscle preservation during semaglutide or tirzepatide treatment. GLP-1 medications drive impressive weight loss, but a meaningful share of that loss can be lean mass. Some integrative and peptide-focused providers position MOTS-c alongside GLP-1 to sustain training output during a calorie deficit. The clinical evidence for this specific combination is anecdotal; resistance training and adequate protein still do most of the work.
Aerobic Exercise Capacity and Recovery
In a mouse study, MOTS-c improved running time and distance and shifted muscle toward slow-twitch endurance fibers (Reynolds et al., 2021; Yuan et al., 2021). In healthy humans, MOTS-c rises naturally with aerobic exercise (Reynolds et al., 2021). The clinical use case is the master's-age endurance athlete or the post-illness patient rebuilding aerobic base. However, the caveat is that MOTS-c was added to the World Anti-Doping Agency's prohibited list in 2024 as an AMP-activated protein kinase (AMPK) activator under category S4.4 (metabolic modulators), so it's off-limits to anyone subject to testing.
Mitochondrial Support and Age-Related Fatigue
This is the most speculative bucket. Endogenous MOTS-c levels decline with age and are lower in several age-related diseases (Kong et al., 2023). Some longevity providers use a low-frequency protocol as part of a broader mitochondrial-support stack. The human evidence consists of mechanisms and clinical observation.
What the Evidence Supports
The strongest MOTS-c data come from preclinical models, with a single direct human trial serving as an early clinical bridge. In a 2015 mouse study, MOTS-c administration prevented diet-induced obesity in high-fat-fed mice and improved whole-body insulin sensitivity, with roughly a 30% increase in glucose disposal during hyperinsulinemic clamp testing (Lee et al., 2015). Follow-up work showed MOTS-c moves into the nucleus to regulate stress-response genes (Kim et al., 2018\) and reduces vascular calcification through AMPK signaling in rats (Wei et al., 2019).
In rodent exercise studies, combining MOTS-c with training improved cardiac performance more than training alone (Yuan et al., 2021). In humans, skeletal muscle MOTS-c rises with exercise (D'Souza et al., 2020), and in women with PCOS, MOTS-c responds to lipid and insulin signaling as predicted (Ramanjaneya et al., 2019).
The one human interventional trial is the CB-4211 Phase 1b study in 20 adults with NAFLD: ALT down 21%, AST down 28%, fasting glucose down 6%, and no serious adverse events at four weeks (CohBar Inc., 2021).
Where the Evidence Is Limited
The popular framing of MOTS-c has moved faster than the data. Only a handful of human trials are registered, and most of what's repeated online about fat loss, longevity, and athletic performance comes from mouse studies. CB-4211 reached Phase 1b, but commercial development was deprioritized after CohBar's 2023 merger with Morphogenesis to form TuHURA Biosciences, which pivoted away from the mitochondrial peptide pipeline.
Skeptic voices have pushed back hard on the "exercise in a vial" framing. Evidence-based nutrition researchers, including Layne Norton, have repeatedly made the case that AMPK activation is one piece of what exercise does, not a substitute for the mechanical, cardiovascular, and neuromuscular adaptations of training.
Barbell Medicine's late-2025 podcast episode "The Peptide Market Audit," hosted by Drs. Jordan Feigenbaum and Austin Baraki, reached a similar verdict on the peptide market overall: mechanistically interesting in places, evidentially thin in humans. Renaissance Periodization's Mike Israetel has called peptides broadly an overhyped fitness trend.
MOTS-c has a plausible mechanism, an early human signal in fatty liver, and a thin clinical record built on providers' observations. It complements exercise rather than replacing it, and it does not outperform GLP-1 medications for fat loss; the long-term human safety record rests on clinical experience plus one small trial.
Safety and Regulation
The regulatory picture for MOTS-c in the United States is split between off-label clinical access and an unregulated online market, and the difference matters more for safety than for the science. MOTS-c is not FDA-approved for any indication, so US patients have historically obtained it through 503A compounding pharmacies, the legal pathway that allows a licensed pharmacy to prepare a medication for a specific patient with a prescription. That access has narrowed since the FDA's 2024 enforcement actions on peptide compounding. A separate "research peptide" market also sells vials online without a prescription, with no quality oversight; sourcing matters more here than for most therapies.
Reported side effects in clinical practice are mild: injection-site reactions, occasional nausea, and sometimes a transient rise in homocysteine through the folate-cycle effect. Clinicians typically screen folate and B12 levels before starting and recheck them during a cycle. People who are pregnant, breastfeeding, have active cancer, or have significant baseline homocysteine elevation should not use it. MOTS-c is prohibited year-round under WADA category S4.4 (AMPK activators / metabolic modulators) for athletes subject to testing.
The Future of MOTS-c
Three threads of research are likely to shape where MOTS-c goes next. The first is a possible return of the NASH analog: CB-4211 showed sufficient early signal to warrant a follow-on trial under different sponsorship. The second is exercise medicine, where academic groups are studying MOTS-c for older adults who can't tolerate high-intensity training but need the metabolic benefits, including post-cancer and post-stroke rehabilitation. The third is the broader category MOTS-c opened up, with humanin, SHLP2, and SHLP6 being characterized in parallel.
Takeaway
MOTS-c is one of the more mechanistically interesting peptides in clinical use today. It came out of a 2015 USC discovery that mitochondrial DNA encodes a small signaling peptide of its own, which reframed how researchers think about mitochondria's role in whole-body metabolism. In practice, it's used to address insulin resistance, fatty liver, and aerobic capacity, and to preserve lean mass, alongside GLP-1 treatment. The early human data is encouraging but small; the animal data is more developed.
MOTS-c is an intriguing peptide with a plausible biological mechanism and encouraging early research, particularly in metabolic health and fatty liver disease. At the same time, human studies remain limited, and many of the claims circulating online are based on animal research rather than large clinical trials. For people interested in MOTS-c, it's best viewed as a potential complement to exercise, nutrition, and other evidence-based treatments, not a replacement for them.
If you’re looking for a provider, you can browse vetted MOTS-c peptide therapy clinics across the U.S. in our directory.
